Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
HASBROUCK HEIGHTS, N.J., May 08, 2017 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Following Nymox's announcement of the Company's filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EDT on Wednesday May 10, 2017. The call-in number will be reported prior to the teleconference call.
Shareholder questions in advance are welcomed and can be sent by email to: [email protected]
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.
Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com
